Companies ›Healthcare ›ARAY.O

ARAY.O — NASDAQ Advanced Medical Equipment & Technology

Accuray Inc

$0,27

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

31,6M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

2,0 %

ROE

-2,0 %

Net margin

-0,3 %

Debt / equity

1,68

Beta

—

52w range

—

Volume

57,5k

Day range

—

Prev close

$0,37

Open

—

Next earnings

2026-08-09

Ex-dividend

—

TR 1Y

—

About

Accuray Inc develops and markets advanced medical equipment and technology, primarily focused on radiation therapy systems for the treatment of cancer.

Business. Accuray Inc (ARAY.O) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, primarily generating revenue through product sales. Accuray is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

Generated · model-assisted

Sell-side consensus

BUY2 analysts

2 buy0 hold0 sell

Avg 12m price target2,52

Analyst recommendations

2 analysts · consensus Buy

Buy2

Hold0

Sell0

12-month price target

2,52

Consensus of sell-side coverage.

Upcoming events

EarningsFY 2026 earnings (expected)2026-08-09 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

2 analysts · indicative

Ownership→

BlackRock Institutional Trust Company, N.A.

largest disclosed fund holder

Profitability→

-2,0 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ARAY.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ARAY.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsFY 2026 earnings (expected)2026-08-09 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

Briefing · model-assisted

Accuray Incorporated (ARAY.O) has entered the monitoring scope for the first time, establishing a baseline for future analysis with no prior data available for delta computation. This initial snapshot reveals a shareholder base comprising 24 top holders, providing a foundational view of the company's ownership structure as it begins to be tracked in this financial context. The most material development in this initial report is the detection of multiple notable additions to the shareholder registry, all dated as of March 31, 2026. These changes were detected on June 20, 2026, and include new positions from several investors, indicating fresh capital allocation or portfolio adjustments by these entities during the first quarter of 2026. Specifically, the data highlights new holdings from investors identified by IDs 478, 481, 486, 487, 499, 500, and 502. The largest of these new positions belongs to investor ID 499, who holds 1,401,766 shares valued at approximately $0.54 million, representing a weight of roughly 0.0097% in their portfolio. Other significant new entries include investor ID 500 with 861,635 shares and investor ID 502 with 717,045 shares, while smaller positions were established by investors ID 487, 486, 481, and 478. These new holdings contribute to the broader profile of Accuray, which currently has one officer and is followed by five analysts, though it holds no index memberships. The emergence of these new shareholders provides early insight into institutional or significant investor interest in the company, setting the stage for tracking future changes in ownership concentration and market sentiment.

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Accuray Inc (ARAY.O) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, primarily generating revenue through product sales. Accuray is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

AI synthesis

GENERATED

Accuray Inc has a market capitalization of $33.83 million and a price-to-book ratio of 0.42, indicating a significant discount to its book value. The company's liquidity position is characterized by $57.42 million in cash and equivalents, but this is offset by $136.52 million in long-term debt, resulting in a debt-to-equity ratio of 1.68. The current ratio of 1.65 suggests the company has sufficient short-term assets to cover its short-term liabilities, but the overall capital structure is heavily leveraged.

Profitability metrics show a mixed picture. The company reported a net loss of $1.59 million and an operating income of $9.31 million, translating to a return on equity of -1.96% and a return on assets of -0.34%. These figures are below the industry median for return on equity and return on assets, which are typically positive for firms in the healthcare equipment sector. The gross profit margin of 32.06% is relatively strong, but the net loss indicates inefficiencies in operating expenses or other cost structures.

Geographically, Accuray's revenue is not disclosed by region, but the company's primary market is the United States, with a significant presence in international markets. The lack of detailed geographic breakdown limits the ability to assess regional risk exposure. The company's revenue concentration is not explicitly stated, but the absence of segment-specific data suggests a relatively undiversified business model.

Looking ahead, the company's growth trajectory is uncertain. The current fiscal year is expected to show a modest increase in revenue, but the next fiscal year's outlook is not provided. The company's operating cash flow of $2.86 million and free cash flow of $287,000 are positive signs, but they are insufficient to cover the net loss. The capital expenditure of -$4.27 million indicates a reduction in investment, which may signal a strategic shift or financial constraints.

Risk factors include a medium liquidity risk due to the company's high debt levels and a net cash position that is negative after subtracting total debt. The dilution risk is assessed as low, but the company's financial leverage and net loss could impact its ability to raise additional capital without diluting existing shareholders. The risk assessment also highlights the need for careful monitoring of the company's debt management and cash flow generation.

Recent events include analyst estimates that suggest a mean price target of $2.52, with a median price target of $2.52 and a strong buy recommendation from two analysts. These estimates indicate a positive sentiment among analysts, but the company's current financial performance does not fully support such optimism. The lack of recent filings or transcripts limits the ability to assess the company's strategic direction and operational performance in detail.

Key takeaways

Accuray Inc is significantly undervalued relative to its book value, with a price-to-book ratio of 0.42.
The company's capital structure is highly leveraged, with a debt-to-equity ratio of 1.68 and a current ratio of 1.65.
Despite a strong gross profit margin, the company reported a net loss, indicating operational inefficiencies.
Analysts have a positive outlook, with a mean price target of $2.52 and a strong buy recommendation from two analysts.
The company's liquidity position is medium risk, and its net cash is negative after subtracting total debt.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$0,27

Market cap

$33.8M

Enterprise valueⓘ

$112.9M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

39.5x

P / Bⓘ

0.4x

P / Tangible bookⓘ

0.4x

Tangible book

$81.2M

Net cashⓘ

-$79.1M

Current ratioⓘ

1.6

Debt / equityⓘ

1.7

ROAⓘ

-0.3%

ROEⓘ

-2.0%

Cash conversionⓘ

-180.0%

CapEx / revenueⓘ

-0.9%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships26 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries26

EX21:0e98cc0b1589EX21:0e98cc0b1589Subsidiarie97%Source ↗

EX21:1667d437d6edEX21:1667d437d6edSubsidiarie97%

EX21:1f20d0b77735EX21:1f20d0b77735Subsidiarie97%

EX21:21bd3229a131EX21:21bd3229a131Subsidiarie97%Source ↗

EX21:2c598436e557EX21:2c598436e557Subsidiarie97%Source ↗

EX21:371696ef766eEX21:371696ef766eSubsidiarie97%Source ↗

EX21:4bdf1bb453a6EX21:4bdf1bb453a6Subsidiarie97%

EX21:4c799454ccf3EX21:4c799454ccf3Subsidiarie97%Source ↗

EX21:51f4518d928bEX21:51f4518d928bSubsidiarie97%

EX21:52071cd164fdEX21:52071cd164fdSubsidiarie97%

EX21:59ae856cd788EX21:59ae856cd788Subsidiarie97%Source ↗

EX21:659503d9a30fEX21:659503d9a30fSubsidiarie97%

EX21:72258f1eb6f3EX21:72258f1eb6f3Subsidiarie97%

EX21:746d6c435208EX21:746d6c435208Subsidiarie97%

EX21:76201e78aca7EX21:76201e78aca7Subsidiarie97%Source ↗

EX21:797c1ff77f2eEX21:797c1ff77f2eSubsidiarie97%

EX21:8700c72672ccEX21:8700c72672ccSubsidiarie97%

EX21:9922acec2b63EX21:9922acec2b63Subsidiarie97%

EX21:ac7974d93df8EX21:ac7974d93df8Subsidiarie97%

EX21:b9c8036abb83EX21:b9c8036abb83Subsidiarie97%

EX21:c2fdde4127bfEX21:c2fdde4127bfSubsidiarie97%

EX21:c32f5de8269aEX21:c32f5de8269aSubsidiarie97%Source ↗

EX21:d35dece938bdEX21:d35dece938bdSubsidiarie97%

EX21:def6dfcafc1dEX21:def6dfcafc1dSubsidiarie97%

EX21:f55b8a8b2033EX21:f55b8a8b2033Subsidiarie97%

EX21:f7a21f23863eEX21:f7a21f23863eSubsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs ARAY · multiples and returns

TMO—

Thermo Fisher Scientific Inc

$574,03

214,1B USD

P/E

29,4x

— vs self

Div yield

0,3 %

— vs self

ROE

12,9 %

+14,9 vs self

DHR—

Danaher Corp

$197,50

140,1B USD

P/E

38,2x

— vs self

Div yield

—

— vs self

ROE

6,9 %

+8,8 vs self

GEHC—

GE HEALTHCARE TECHNOLOGIES INC.

$69,72

31,9B USD

P/E

13,6x

— vs self

Div yield

0,2 %

— vs self

ROE

19,5 %

+21,5 vs self

PHG—

PHG

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BSX—

Boston Scientific Corp

$48,54

72,6B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

ISRG—

INTUITIVE SURGICAL, INC.

$376,00

133,2B USD

P/E

287,7x

— vs self

Div yield

—

— vs self

ROE

3,6 %

+5,5 vs self

A—

Agilent Technologies Inc

$139,80

39,6B USD

P/E

29,0x

— vs self

Div yield

0,8 %

— vs self

ROE

19,3 %

+21,3 vs self

EW—

Edwards Lifesciences Corp

$88,82

51,6B USD

P/E

44,3x

— vs self

Div yield

—

— vs self

ROE

10,4 %

+12,3 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,28

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,28
Revenue	—no estimate	—no estimate	443,2M USD
Operating income	—no estimate	—no estimate	-8,0M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 5 %

Probability

5 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-16 · 1,8× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution2 analysts

Strong buy2

Buy0

Hold0

Sell0

Strong sell0

12-month price target$2,52 · Median $2,52

Low $2,00High $3,05

Operating income · consensus-8,0M USD

EPS surprise

+93,0 %

reported vs consensus · beat

Revenue surprise

+3,5 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$2,00

Mean$2,52

Median$2,52

High$3,05

Spot$0,27

+849.2 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin2,0 %Above median

Net Margin-0,4 %Above median

ROE-2,0 %Above median

Capex / Rev-0,9 %Above P75

D/E1,68Bottom quartile

Cash Conv-1,80Bottom quartile

Corporate actions / M&A

M&A probabilityconf —

Probability

5 %

Base rate

3 %

Band

Moderate

180-day horizon · target 2027-01-16 · 1,8× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 6 813 821 sh8 exercises · 14 grants14 insiders

Miele Paul MichaelSVP, Chief Commercial Officer · Restricted Stock Units → Common StockAcquired 650 000grant · 2026-05-29
TCW GROUP INC10% owner · Warrant to Purchase Common Stock → Common StockAcquired 105 882 @ $1,50other · 2026-05-19
TCW GROUP INC10% owner · Warrant to Purchase Common Stock → Common StockAcquired 75 630 @ $1,25other · 2026-05-19
TCW GROUP INC10% owner · Warrant to Purchase Common Stock → Common StockAcquired 60 504 @ $0,01other · 2026-05-19
TCW GROUP INC10% owner · Warrant to Purchase Common Stock → Common StockAcquired 1 010 028 @ $1,25other · 2026-05-19
TCW GROUP INC10% owner · Warrant to Purchase Common Stock → Common StockAcquired 1 414 040 @ $1,50other · 2026-05-19
TCW GROUP INC10% owner · Warrant to Purchase Common Stock → Common StockAcquired 808 023 @ $0,01other · 2026-05-19
Peralta LeonelSVP, Chief Operations Officer · Restricted Stock Units → Common StockDisposed 83 723exercise · 2026-02-28
Scott Byron CDirector · Restricted Stock Units → Common StockDisposed 9 433exercise · 2025-12-31
Chalke SandeepSVP, Chief Commercial Officer · Restricted Stock Units → Common StockDisposed 50 314exercise · 2025-11-29
Pervaiz AliSVP Chief Financial Officer · Restricted Stock Units → Common StockDisposed 44 025exercise · 2025-11-29
La Neve Stephen R.Director, CEO · Restricted Stock Units → Common StockAcquired 1 064 814grant · 2025-11-28
Galbato ChanDirector · Restricted Stock Units → Common StockAcquired 56 603grant · 2025-11-28
MAYER STEVEN FDirector · Restricted Stock Units → Common StockAcquired 56 603grant · 2025-11-28
MAYER STEVEN FDirector · Performance Stock Award → Common StockAcquired 1 250 000grant · 2025-11-28
Scott Byron CDirector · Restricted Stock Units → Common StockAcquired 56 603grant · 2025-11-28
Le Grand Anne BryceDirector · Restricted Stock Units → Common StockAcquired 56 603grant · 2025-11-28
Hindman James M.Director · Restricted Stock Units → Common StockAcquired 56 603grant · 2025-11-28
HUSS BEVERLY ADirector · Restricted Stock Units → Common StockAcquired 56 603grant · 2025-11-28
WHITTERS JOSEPH EDirector · Restricted Stock Units → Common StockAcquired 56 603grant · 2025-11-28
Nishimura MikaDirector · Restricted Stock Units → Common StockAcquired 56 603grant · 2025-11-28
Pervaiz AliSVP Chief Financial Officer · Restricted Stock Units → Common StockAcquired 90 000grant · 2025-11-28
Chalke SandeepSVP, Chief Commercial Officer · Restricted Stock Units → Common StockAcquired 110 000grant · 2025-11-28
Peralta LeonelSVP, Chief Operations Officer · Restricted Stock Units → Common StockAcquired 125 000grant · 2025-11-28
MAYER STEVEN FDirector · Restricted Stock Units → Common StockDisposed 45 620exercise · 2025-11-21

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Ev To Operating Cash Flow
enterprise_value / operating_cash_flow
Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Accuray Inc Market data — financials · 2026-05-27
Accuray Inc Market data — analyst estimates · 2026-05-27
Accuray Inc Market data — ESG · 2026-05-27

Ownership & reference

Top holders

BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$15M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$5M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$1M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Leadership

Suzanne C. WinterPresident, Chief Executive Officer

Insider activity

Net buying3 buys · 0 sellsnet $135K8 insiders · last 365d

Chalke SandeepSVP, Chief Commercial Officer · Common StockOther 40 000 @ $0,39$16K · 2026-03-31
Peralta LeonelSVP, Chief Operations Officer · Common StockOther 28 969 @ $0,55$16K · 2026-02-28
Peralta LeonelSVP, Chief Operations Officer · Common StockOther 83 723 · 2026-02-28
MAYER STEVEN FDirector · Common StockBought 54 875 @ $0,56$31K · 2026-02-20
MAYER STEVEN FDirector · Common StockBought 69 000 @ $0,53$37K · 2026-02-19
MAYER STEVEN FDirector · Common StockBought 126 125 @ $0,53$67K · 2026-02-18
Scott Byron CDirector · Common StockOther 9 433 · 2025-12-31
Scott Byron CDirector · Common StockOther 3 774 @ $0,82$3K · 2025-12-31
Chalke SandeepSVP, Chief Commercial Officer · Common StockOther 64 477 @ $1,02$66K · 2025-12-01
Pervaiz AliSVP Chief Financial Officer · Common StockOther 57 341 @ $1,02$58K · 2025-12-01
Pervaiz AliSVP Chief Financial Officer · Common StockOther 44 025 · 2025-11-29
Chalke SandeepSVP, Chief Commercial Officer · Common StockOther 50 314 · 2025-11-29
Galbato ChanDirector · Common StockOther 50 000 · 2025-11-28
MAYER STEVEN FDirector · Common StockOther 895 391 · 2025-11-28
Scott Byron CDirector · Common StockOther 56 603 · 2025-11-21
Scott Byron CDirector · Common StockOther 22 642 @ $1,05$24K · 2025-11-21
Nishimura MikaDirector · Common StockOther 56 603 · 2025-11-21
WHITTERS JOSEPH EDirector · Common StockOther 56 603 · 2025-11-21
MAYER STEVEN FDirector · Common StockOther 45 620 · 2025-11-21

Short positioning

4.7Mshares short-2.3% vs prior

3.43days to cover

45.8%short of daily vol

5.2Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ARAY.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00M&A prob5 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -22.6%Derived (calculated)
Current ratio (FY 2025-12-31): 1.47xDerived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -6.3%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -8.3%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -34.0%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 11.5%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 7.39xDerived (calculated)
Long-term debt (annual): USD 135.89MSEC XBRL filing
Total assets (annual): USD 448.01MSEC XBRL filing
Current liabilities (annual): USD 199.44MSEC XBRL filing
Shares outstanding (annual): 118.79MSEC XBRL filing
Current assets (annual): USD 292.39MSEC XBRL filing
Shareholders' equity (annual): USD 53.42MSEC XBRL filing
Total liabilities (annual): USD 394.59MSEC XBRL filing
Cash & equivalents (annual): USD 41.3MSEC XBRL filing
Capex (YoY) (2025-06-30 vs 2024-06-30): 18.6%Derived (calculated)
Revenue (YoY) (2025-06-30 vs 2024-06-30): 2.7%Derived (calculated)
R&D expense (YoY) (2025-06-30 vs 2024-06-30): -3.6%Derived (calculated)
Operating income (YoY) (2025-06-30 vs 2024-06-30): 1,455.4%Derived (calculated)
Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): 124.0%Derived (calculated)
Net income (YoY) (2025-06-30 vs 2024-06-30): 89.8%Derived (calculated)
Net margin (FY 2025-06-30): -0.3%Derived (calculated)
Gross margin (FY 2025-06-30): 32.1%Derived (calculated)
Gross profit (YoY) (2025-06-30 vs 2024-06-30): 2.8%Derived (calculated)

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date

2026-07-29 22:34 UTCEVENTHa Price Listing ARAY remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 122 consecutive trading days (last close $0.3407). cure deadline 2027-01-17 (172 days remaining).

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-21 02:57 UTCHOLDERInstitutional holding changed

2026-06-21 02:57 UTCHOLDER19 institutional position changes flagged

2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated

2026-06-04FILINGFORM 8-K →

2026-05-29 00:00 UTCINSIDER7 insider transactions — 2026-05 7 derivative

2026-05-29INSIDERMiele Paul Michael acquired 650.0k sh Restricted Stock Units — SVP, Chief Commercial Officer

2026-05-19INSIDERTCW GROUP INC acquired 1.41M sh Warrant to Purchase Common Stock — 10% owner

2026-05-19INSIDERTCW GROUP INC acquired 808.0k sh Warrant to Purchase Common Stock — 10% owner

2026-05-19INSIDERTCW GROUP INC acquired 75.6k sh Warrant to Purchase Common Stock — 10% owner

2026-05-19INSIDERTCW GROUP INC acquired 105.9k sh Warrant to Purchase Common Stock — 10% owner

2026-05-19INSIDERTCW GROUP INC acquired 60.5k sh Warrant to Purchase Common Stock — 10% owner

2026-05-19INSIDERTCW GROUP INC acquired 1.01M sh Warrant to Purchase Common Stock — 10% owner

2026-05-06FILINGFORM 10-Q →

2026-05-06FILINGFORM 8-K →

2026-04-28FILINGFORM 8-K →

2026-04-07FILINGFORM 8-K →

2026-04-06FILINGFORM 8-K →

2026-03-31 00:00 UTCINSIDER1 insider transaction — 2026-03

2026-03-31INSIDERChalke Sandeep transacted 40.0k sh — SVP, Chief Commercial Officer ~$16k

2026-03-19FILINGFORM 8-K →

2026-02-28 00:00 UTCINSIDER6 insider transactions — 2026-02 · net buy $119k 1 derivative

2026-02-28INSIDERPeralta Leonel transacted 29.0k sh — SVP, Chief Operations Officer ~$16k

Showing the 40 most recent of 78 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread